PM
VINC icon

Prosight Management’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Prosight Management’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-110,325
Closed -$1.58M – 53
2024
Q3 		$1.58M Sell
110,325
-14,096
-11% -$193K 0.39% 37
2024
Q2 		$2.02M Buy
+124,421
New +$3.12M 0.6% 31

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Prosight Management's VINC Position: Q4 2024 in Review

Prosight Management sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2024, closing a stake of 110,325 shares — an estimated $1.58M sold.

Prosight Management first reported a position in VINC in Q2 2024 and held it in 2 quarters. The position peaked at $2.02M in Q2 2024. 22 funds tracked by Wall St. Rank hold VINC as of Q4 2024.

  • Prosight Management reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Prosight Management sold 110,325 Vincerx Pharma, Inc. Common Stock shares in Q4 2024, an estimated $1.58M.
  • Prosight Management first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2024 and held it in 2 quarters.
  • Prosight Management's Vincerx Pharma, Inc. Common Stock position peaked at $2.02M in Q2 2024.
  • 22 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2024.

Based on Prosight Management's 13F filing for Q4 2024, filed 14 Feb 2025.